Trade ORIC Pharmaceuticals, Inc. - ORIC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.06 |
| Open | 4.99 |
| 1-Year Change | -37.94% |
| Day's Range | 4.99 - 5.35 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 28, 2025 | 5.05 | 0.06 | 1.20% | 4.99 | 5.38 | 4.98 |
| Apr 25, 2025 | 5.06 | 0.07 | 1.40% | 4.99 | 5.13 | 4.88 |
| Apr 24, 2025 | 5.14 | 0.13 | 2.59% | 5.01 | 5.22 | 5.01 |
| Apr 23, 2025 | 5.13 | -0.26 | -4.82% | 5.39 | 5.62 | 5.10 |
| Apr 22, 2025 | 5.18 | 0.20 | 4.02% | 4.98 | 5.25 | 4.89 |
| Apr 21, 2025 | 4.84 | 0.35 | 7.80% | 4.49 | 5.15 | 4.49 |
| Apr 17, 2025 | 4.73 | 0.24 | 5.35% | 4.49 | 4.75 | 4.49 |
| Apr 16, 2025 | 4.66 | -0.27 | -5.48% | 4.93 | 4.93 | 4.59 |
| Apr 15, 2025 | 5.02 | 0.13 | 2.66% | 4.89 | 5.34 | 4.89 |
| Apr 14, 2025 | 5.07 | 0.09 | 1.81% | 4.98 | 5.13 | 4.88 |
| Apr 11, 2025 | 4.88 | 0.64 | 15.09% | 4.24 | 4.91 | 4.09 |
| Apr 10, 2025 | 4.27 | -0.08 | -1.84% | 4.35 | 4.58 | 4.16 |
| Apr 9, 2025 | 4.63 | 0.58 | 14.32% | 4.05 | 4.98 | 3.87 |
| Apr 8, 2025 | 4.22 | -0.67 | -13.70% | 4.89 | 4.89 | 4.09 |
| Apr 7, 2025 | 4.54 | 0.06 | 1.34% | 4.48 | 4.96 | 4.36 |
| Apr 4, 2025 | 4.83 | -0.18 | -3.59% | 5.01 | 5.12 | 4.74 |
| Apr 3, 2025 | 5.21 | -0.08 | -1.51% | 5.29 | 5.36 | 5.09 |
| Apr 2, 2025 | 5.74 | 0.45 | 8.51% | 5.29 | 5.95 | 5.29 |
| Apr 1, 2025 | 5.51 | 0.06 | 1.10% | 5.45 | 5.64 | 5.23 |
| Mar 31, 2025 | 5.54 | -0.26 | -4.48% | 5.80 | 5.83 | 5.49 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
ORIC Pharmaceuticals, Inc. Company profile
About ORIC Pharmaceuticals Inc
ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its product candidates include ORIC-101, ORIC-533, ORIC-944 and ORIC-114. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its ORIC-944, is being developed for prostate cancer and breast cancer.
Financial summary
BRIEF: For the nine months ended 30 September 2021, ORIC Pharmaceuticals Inc revenues was not reported. Net loss increased 23% to $55.9M. Higher net loss reflects Research and development - Balancing val increase from $15.4M to $36.5M (expense), General and administrative - Balancing increase of 93% to $10.2M (expense), Stock-based Compensation in SGA increase from $1.9M to $5.8M (expense).
| Industry: | Bio Therapeutic Drugs |
240 E. Grand Ave
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com